Collection of Whole Blood Specimens from Pregnant Women At Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted from Maternal Plasma

Sequenom, Inc.14 sites in 2 countries2,000 target enrollmentMay 2011

ConditionsDown Syndrome Fetal Aneuploidy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Down Syndrome
Sponsor: Sequenom, Inc.
Enrollment: 2000
Locations: 14
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.

Detailed Description

To collect specimens for the purpose of developing a prenatal aneuploidy test. The test will analyze circulating cell free fetal (ccff) nucleic acid from blood samples from pregnant women who have an increased risk indicator/s for fetal chromosomal aneuploidy and are undergoing invasive prenatal diagnosis by chorionic villus sampling (CVS) and/or genetic amniocentesis. The results of the ccff aneuploidy test will be compared to the chromosomal analysis obtained via CVS or genetic amniocentesis.

Registry

clinicaltrials.gov

Start Date

May 2011

End Date

March 2026

Last Updated

last year

Study Type

Observational

Sex

Female

Investigators

Sponsor

Sequenom, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•pregnant between 10 and 22 weeks gestation
•18 years of age or older
•provides signed and dated informed consent
•subject is at increased risk for fetal aneuploidy
•subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis
•subject agrees to provide the genetic results of the invasive procedure